USPTO serial 79453224
ALTHEOME
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- PEISECKI, MARK A
- Law office
- TMEG LAW OFFICE 105
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with ALTHEOME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Biotechnological research services; scientific research services; laboratory research services; laboratory testing services; design and product development services; scientific analysis services; biological research services; medical research services; research and development services; clinic trial services; DNA sequencing for medical research and technology research purposes; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinic trial services, and DNA sequencing for medical research and technology research purposes, all relating to proteomics, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinic trial services, and DNA sequencing for medical research and technology research purposes, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinic trial services, and DNA sequencing for medical research and technology research purposes, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; design and development of diagnostic assays, devices, and platforms; bioinformatic services; biostatistics services; data and database services; data and database services, namely data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases; computer modelling and computer simulation services; cloud computing services; design and development artificial intelligence and machine learning models; bioinformatic services, biostatistics services, data and database services, data and database services, namely data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all relating to proteomics, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; bioinformatic services, biostatistics services, data and database services, data and database services, namely data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; bioinformatic services, biostatistics services, data and database services, data and database services, namely data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; information, advisory and consultancy services relating to the aforesaid. | ACTIVE | — |
| 044 | Pathological testing for diagnostic and treatment purposes; medical testing and analysis services relating to the diagnosis and treatment of disease; laboratory analysis services relating to the diagnosis and treatment of persons; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating to the diagnosis and treatment of disease, and laboratory analysis services relating to the diagnosis and treatment of persons, all relating to proteomics, proteomics profiling services, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating to the diagnosis and treatment of disease, and laboratory analysis services relating to the diagnosis and treatment of persons, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; medical services; medial testing services; medical diagnostic services; medical analysis services; medical screening services; medical services, medial testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to proteomics, proteomics profiling services, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; medical services, medial testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; medical services, medial testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; information, advisory and consultancy services relating to the aforesaid. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 8, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 1, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 31, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 24, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 10, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 10, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 2, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |